Skip to content

Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia

Prospective Cohort Study: Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02325323
Acronym
GASTRIMED
Enrollment
2000
Registered
2014-12-24
Start date
2014-05-31
Completion date
2015-06-30
Last updated
2014-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Cancer

Keywords

stomach cancer, gastric intestinal metaplasia, prospective cohort, low grade dysplasia, high grade dysplasia, prognosis factor, gastric cancer risks

Brief summary

This prospective cohort study aims to assess the incidence of gastric cancer in patients with intestinal metaplasia in body of stomach or angular incisure. As secondary objectives, among the patients included in the cohort, the study will: * assess the incidence of low grade dysplasia, * assess the incidence of high grade dysplasia in patients with low grade dysplasia, * identify risk factors of progression to dysplasia and gastric cancer.

Detailed description

This is a French nationwide prospective study. 2000 patients will be enrolled by 3500 gastroenterologists, either in private or public healthcare settings. All patients will undergo an endoscopy with gastric sampling in order to biopsy: * 1 sample each in anterior and posterior surfaces of antrum * 1 sample in lesser curvature * 1 sample each in anterior and posterior surfaces of body of stomach Patients will be contacted every 12 months and followed up for 3 years by their gastroenterologist. The follow-up will be performed according to the 2012 European Guideline on Management of Precancerous Conditions and Lesions in the stomach (Endoscopy 2012, Jan; 44(1): 74-94). Patients will also receive a 6-monthly phone call from their gastroenterologist in order to know if any gastric symptom has appeared. At any time, patients should contact their gastroenterologist to inform them about new gastric symptoms. During follow-up, the frequency of gastroscopy with biopsy depends on the stage of lesions: * patients with intestinal metaplasia: gastroscopy at 36 months. * patients with dysplasia: an annual gastroscopy will be performed. In case of low grade dysplasia confirmed by pathologist at inclusion, patients will undergo 1 year later another endoscopy with gastric sampling in order to biopsy: * 4 circumferential samplings of antrum * 1 sampling of curvature * 4 circumferential samplings of body of stomach

Interventions

None listed

Sponsors

Société nationale française de gastro-entérologie
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years. * Gastroscopic examination with biopsy in the 6 months preceding inclusion, with intestinal metaplasia in body of stomach or angular incisure. * Patient does not oppose to participate to the study.

Exclusion criteria

* Progressive concomitant disease with life expectancy less than 3 years. * Gastric cancer at the time of inclusion. * Patient with previous oesophageal cancer. * Patient with previous gastric surgery. * Anticipated obstacles to follow-up during the study (e.g., understanding difficulties, homelessness).

Design outcomes

Primary

MeasureTime frameDescription
Incidence of gastric cancer or high grade dysplasia of the gastric mucosa3 yearsIncidence of gastric cancer or high grade dysplasia of the gastric mucosa during the 3-year follow-up.

Secondary

MeasureTime frameDescription
Percentage of development of low grade dysplasia3 yearsPercentage of development of low grade dysplasia in patients initially with intestinal metaplasia without dysplasia.
Percentage of development of gastric cancer or high grade dysplasia3 yearsPercentage of development in 3 years of gastric cancer or high grade dysplasia lesion, in patients initially with low grade dysplasia.

Countries

France

Contacts

Primary ContactDominique LAMARQUE, MD, PhD
dominique.lamarque@apr.aphp.fr+33 1 49 09 53 25

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026